The 2022 MTI 100 list includes a new intake of rapidly growing companies, with the result that the threshold for inclusion has risen to over $400m. Many companies in the lower reaches of previous years’ rankings have fallen below the threshold.
The leading companies are those familiar faces that have long shaped the structure of the medtech industry and driven its growth. More than usual swapping of places is evident among the Top 12, as a result of past M&A, portfolio reshaping, strategic management interventions and the waning significance of COVID-associated revenues in 2022.
Figures shown are for the year ended 31 December 2022, except where noted, while most Japanese companies’ 31 March 2023 year-ends are reflected.
The lists were compiled and edited by Medtech Insight and Meddevicetracker Reports.
This page was updated on 20 December 2023. Unless noted, the tables show reported external medtech-specific sales values of publicly owned companies at manufacturer level and exclude service revenues unless noted. Average annual exchange US dollar exchange rates from 31 December 2022 are used for comparative purposes, regardless of the company’s financial year end (for the major currencies: $1.054 to the Euro; $0.0076 to the Yen; $1.048 to the Swiss Franc; $1.24 to the £)